

DOI: <http://doi.org/10.32792/utq.jceps.10.01.07>

## Association of Irisin Hormone with Some Physiological and Inflammatory Parameters in Patients with Type 2 Diabetic Mellitus (T2DM) in Thi-Qar Province/ Iraq

Saad H. Al-Badry<sup>1</sup>, Khalid G. Al-Fartoosi<sup>2</sup>

<sup>1,2</sup>Biology Department, College of Science, University of Thi-Qar

Received 2/6/2019

Accepted 23/7/2019

Published 20/1/2020



This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/).

### Abstract:

The present study aimed to assessment of irisin level in patients with the newly onset type 2 "diabetes mellitus" (T2D M ) and the scanning the association of irisin value with some physiological and inflammatory parameters. This study comprised 60 individuals diagnosed in newly onset T2D M and 40 healthy contributors (control group). IL-6 and C-reactive protein(CRP) concentration was calculated in patient who involved in this study. Serum irisin levels in addition to inflammatory factors were evaluated by ELISA kit.

The present study showed a significant increasing ( $P \leq 0.05$ ) of glycohemoglobin (HbA1C) and FBS level in patient with DM2 compared with the control groups ( $6.88 \pm 1.02$  vs  $4.15 \pm 0.56$ ;  $7.85 \pm 1.89$  vs  $4.94 \pm 0.40$ ) respectively. Also, the results explained a significant increased ( $P \leq 0.05$ ) of T-Ch, Tg and LDL level in DM2 group compared with the control group ( $4.27 \pm 0.90$  vs  $4.23 \pm 0.40$ ;  $2.14 \pm 0.86$  vs  $1.89 \pm 0.26$ ;  $2.84 \pm 0.94$  vs  $2.23 \pm 0.52$ ) respectively. Whereas, the results showed a significant decrease ( $P \leq 0.05$ ) of irisin, insulin, C-peptide and HDL in DM2 group compared with the control group ( $22.32 \pm 4.55$  vs  $27.81 \pm 2.93$ ;  $18.29 \pm 3.66$  vs  $27.27 \pm 6.90$ ;  $3.12 \pm 0.99$  vs  $6.03 \pm 0.48$ ;  $1.0 \pm 0.17$  vs  $1.61 \pm 0.37$ ) respectively. On the other hand, the results of inflammatory parameters showed a significant increase ( $P \leq 0.05$ ) of IL-6 and CRP level compared with the control group ( $19.85 \pm 4.97$  vs  $12.0 \pm 1.23$ ;  $8.41 \pm 2.11$  vs  $4.60 \pm 0.35$ ) respectively.

In correlation analysis the results showed a negative association between irisin and (HbA1c) ( $r = -0.152$ ), glucose ( $r = -0.331$ ), insulin ( $r = -0.156$ ), HDL ( $r = -0.114$ ) and BMI ( $r = -0.219$ ). Whereas, the results showed positive correlation between irisin and IL-6 ( $r = 0.115$ ), CRP ( $r = 0.153$ ), C-peptide ( $r = 0.013$ ), T-Ch ( $r = 0.057$ ), Tg ( $r = 0.209$ ) and LDL ( $r = 0.035$ ).

**Keywords:** Irisin, T2DM, inflammatory parameters.

### 1. Introduction:

Diabetes mellitus (DM) is the continual disease common characterizes by hyperglycemia resulting from defects in secretion and/or its activity of insulin (WHO, 2016), its frequency elevate regularly every year. The universal commonness of diabetes, amongst adults were 6.4%, affecting 285 million patients in 2010, and is probable to augment to 7.7% (ie, 439 million individuals) in 2030.

In humans, irisin is produced mainly by skeletal muscle in response to physical activity. It has been demonstrated that irisin plays a pivotal role in inducing fat browning and regulating energy expenditure. New findings from various studies conducted in both animals and humans suggest that irisin can affect

bone and glucose metabolism. In particular, irisin is able to increase bone cortical mass by stimulating the osteoblast pathways, and irisin levels are inversely correlated with the incidence of fragility fractures among postmenopausal women affected by osteoporosis. Most available evidence shows that irisin significantly influences glucose and energy homeostasis (Endocrinologica, 2017).

Bostrom *et al.*, (2012) identified the irisin, an energetic metabolism-related myokine. Its secretion involves the increase of peroxisome proliferator- activated receptor-gamma coactivator 1 alpha (PGC1 alpha) in the muscle, induced by exercise, promoting the expression and proteolysis cleavage of Fndc5, a type 1 membrane protein "fibronectin type III domain-containing protein 5", with release the irisin fragment for the blood flow, this hormone promotes a browning process on the white adipose tissue, a encoding for the thermo genesis in the tissue cells, through the increase of the mitochondrial uncoupling protein 1 (UCP1). So, the final effect of the hormonal signal promoted by the irisin is an enlarge on the physical energy spending, with the decrease of the obesity and development on the insulin resistance caused by diet (Bostrom *et al.*, 2012).

Some new studies have shown that the irisin values were lesser in patients with T2DM when compared with the non-diabetics (Arias-Loste *et al.*, 2014), perhaps for a lacking expression of PGC1 alpha in the muscle (Liu *et al.*, 2013). So, part of the diabetic subjects used a variety of medications. This variation also found on other forms of diabetes, like the type 1 diabetes mellitus (T1DM) (Espes and Arlsson, 2015), and gestational diabetes mellitus (GDM) (Ebert *et al.*, 2014). In addition, increases levels of irisin are also linked with other metabolic parameters such as body mass index (BMI), 2 h plasma glucose after OGTT "(oral glucose tolerance test)", HbA1c and triglycerides (Choi *et al.*, 2013). Numerous studies have addressed the relationship between low of serum irisin levels and insulin resistance or diabetes. A lot of studies showed lower circulating irisin levels in type 2 diabetic patients (Zhang *et al.*, 2016), and others explained a negative correlation with fasting glucose in blood and HbA1c (Yan *et al.*, 2014).

This study aimed to measurement of irisin level in patients with newly onset- T2DM and to examine the association between irisin level and glycaemic indices (BMI, fasting blood glucose, fasting insulin, C-peptide and lipid profile and some inflammatory parametrs).

---

## 2. Material and Methods:

### 2.1. Subjects:

The aimed population of this study was 60 male's persons who are already diagnosed as new onset of T2 DM., which referred to the Nasiriyah Endocrine and Diabetes Centre in Thi-Qar province, Iraq during February - August 2018. The patients are diagnosed as newly onset by the consultant medical staff, according to checked clinical examination and biochemical analysis. Another group of apparently healthy individuals represented as the control group. The data was obtained from each patient including ages, BMI, Medications, Other disease, any other chronic disease and medical history. The patients were 60 males and the control grope involved 40 males' individuals. divided was 45-55 years old matched with age in type2 group.

#### 2.1.1. Blood collection:

About (5 mL) of fasting venous sample of T2DM patients and controls divided to two parts the first part was (2ml) putting in tube with anticoagglutination (EDTA tube) this used to determination of HbA1C test, and the second part was (3ml) to obtain of serum.

### 2.2. Evaluation of Body Mass Index (BMI):

"Body mass index (BMI)" is a determine of someone's weight in linked to their height, and then we put these measurements in the equation:

$$\text{BMI} = \text{Weight (kg)} / \text{Height (m)}^2 \text{ (Nuttall, 2015).}$$

### 2.3. Biochemical parameters analysis:

#### 2.3.1. Hormones:

The irisin, insulin and C-peptide hormone, concentration was calculated match up with to the ELIZA., based on the sandwich principle (Miyazawa *et al.*,1999).

### 2.3.2. Biochemical parameters:

#### 2.3.2.1. Evaluation of fasting blood sugar (F.B.S):

Glucose was determined after enzymatic oxidation in the presence of glucose oxidase. The hydrogen peroxide formed reacts under catalysis of peroxidase, with phenol and 4aminophenazone to form a red-violet quinoneimine dye as indicator (Trinder, 1969).

#### 2.3.2.2. HbA1C test:

System reagents for the quantitative determination of HbA1c (Hemoglobin A1c), in human blood, on Beckman Coulter AU analyzers (Jeppsson *et al.*, 2002).

#### 2.3.2.3. Serum cholesterol and Triglyceride:

Enzymetic method described by Allain *et al.*, (1974).

*Cholesterol esters* → *cholesterol* + *free fatty acids*

*Cholesterol* +  $O_2$  → *cholesterol 4 one 3* +  $H_2O_2$

$2H_2O_2$  + *phenol* + *PAP* → *Quinoneimine(pink)* +  $2H_2O$ .

#### Evaluation of " High density lipoprotein" (HDL) 2,2,3,4

The chemical substance is only for healing of specimen previous to calculate of HDL., - C add to reagent for sum cholesterol. "Low density lipoproteins (LDL) very low density (VLDL) " and "chylomicrons" from specimen are precipitate by "phosphotungstic acid (PTA) and magnesium chloride". HDL., C obtained floating following of centrifuged, so then calculated add to sum cholesterol (Badimon *et al.*, 1990).

#### 2.3.2.5. Evaluation of " Low density lipid protein" (L D L):

By the following function (Peter and Kwiterovich, 2004).

$$L D L = Cholesterol\ con. - (Tg \times 5) - H D L\ con. = (mmol/L)$$

### 2.4. Inflammatory parameters:

#### 2.4.1. IL-6:

The Diaclone IL-6 ELISA kit is a solid phase sandwich ELISA for the in-vitro qualitative and quantitative determination of IL-6 in supernatants, buffered solutions or serum and plasma samples. This assay will recognize both natural and recombinant human IL-6 (Azadbakht *et al.*, 2007).

#### 2.4.2. C-Reactive protein (CRP):

I-CHROMA™ CRP and MAU use a sandwich immunodetection method. (Bains *et al.*, 2017).

### 2.5. Statistical Analysis:

All statistical analysis was performed by using the Statistical Package Social Sciences version 20 software (SPSS v.20) for Windows, due to sample T-test.

### 3. Results:

#### 3.1. BMI:

The present study showed a significant increase ( $P \leq 0.05$ ) of BMI level in patient with DM2 compared with the control group ( $25.83 \pm 2.13$  vs  $21.82 \pm 1.65$ ) (table 2.1).

#### 3.2. Biochemical parameters:

The present study showed a significant increase ( $P \leq 0.05$ ) of glycohemoglobin (HbA1C) and FBS level in patient with DM2 compared with the control group ( $6.88 \pm 1.02$  vs  $4.15 \pm 0.56$ ;  $7.85 \pm 1.89$  vs  $4.94 \pm 0.40$ ) respectively (table 2.1). Also, the results explained a significant increased ( $P \leq 0.05$ ) of T-Ch, Tg and LDL level in DM2 group compared with the control group ( $4.27 \pm 0.90$  vs  $4.23 \pm 0.40$ ;  $2.14 \pm 0.86$  vs  $1.89 \pm 0.26$ ;  $2.84 \pm 0.94$  vs  $2.23 \pm 0.52$ ) respectively. Whereas, the results showed a significant decrease ( $P \leq 0.05$ ) of irisin, insulin, C-peptide and HDL in DM2 group compared with the control group ( $22.32 \pm 4.55$  vs  $27.81 \pm 2.93$ ;  $18.29 \pm 3.66$  vs  $27.27 \pm 6.90$ ;  $3.12 \pm 0.99$  vs  $6.03 \pm 0.48$ ;  $1.0 \pm 0.17$  vs  $1.61 \pm 0.37$ ) respectively (table 2.2).

#### 3.3. Inflammatory Parameters:

The results of inflammatory parameters showed a significant increase ( $P \leq 0.05$ ) of IL-6 and CRP level compared with the control group ( $19.85 \pm 4.97$  vs  $12.0 \pm 1.23$ ;  $8.41 \pm 2.11$  vs  $4.60 \pm 0.35$ ) respectively (table 2.1).

#### 3.4. Correlation analysis

In correlation analysis the results showed a negative association between irisin and (HbA1c) ( $r = -0.152$ ), hyperglycemia ( $r = -0.331$ ), insulin ( $r = -0.156$ ), HDL ( $r = -0.114$ ) and BMI ( $r = -0.219$ ). Whereas, the results showed positive correlation between irisin and IL-6 ( $r = 0.115$ ), CRP ( $r = 0.153$ ), C-peptide ( $r = 0.013$ ), T-Ch ( $r = 0.057$ ), Tg ( $r = 0.209$ ) and LDL ( $r = 0.035$ ) (table 2.3).

**Table (2.1): Level of hormonal, physiological and inflammatory parameters in Type 2 DM.**

Parameters	Patient group(GI) DM2 N= 60	Control group N=40	T-value	Sig
BMI	$25.83 \pm 2.13$	$21.82 \pm 1.65$	10.02	0.02
FBG ( mmol/L)	$7.85 \pm 1.89$	$4.94 \pm 0.40$	11.50	0.01
HbA1C ( mmol/L)	$6.88 \pm 1.02$	$4.15 \pm 0.56$	17.03	0.02
Irisin ng/dl	$22.32 \pm 4.55$	$27.81 \pm 2.93$	7.33	0.04
Insulin ng/dl	$18.29 \pm 3.66$	$27.27 \pm 6.90$	7.54	0.03
C-peptide	$3.12 \pm 0.99$	$6.03 \pm 0.48$	18.87	0.04
IL-6	$19.85 \pm 4.97$	$12.0 \pm 1.23$	11.70	0.02
CRP	$8.41 \pm 2.11$	$4.60 \pm 0.35$	13.63	0.01

Parameters	Patient group DM2 N= 60	Control group N=40	T-value	Sig
TG (mmol/L)	2.14 ± 0.86	1.89 ± 0.26	2.06	0.04
T-Ch (mmol/L)	4.27±0.90	4.23 ± 0.40	0.13	0.75
HDL- Ch(mmol/L)	1.0 ± 0.17	1.61 ± 0.37	9.84	0.01
LDL (mmol/L)	2.84 ± 0.94	2.23 ± 0.52	4.10	0.02

**Table (2.2): Level of lipid profile parameters in Type 2 DM.**

**Table(2.3): Correlation analysis between irisin and other parameters.**

Irisin	Correlation	Irisin	C_peptide	Insulin	IL_6	CRPhs	FBS	HbA1c	Chol	TGs	HDL	LDL	BMI
		1	0.013	-0.156	0.115	0.153	-0.331**	-0.152	0.057	0.209	-0.114	0.035	-
	Sig.		0.922	0.234	0.381	0.242	0.010	0.246	0.667	0.108	0.384	0.789	0.093
	N	60	60	60	60	60	60	60	60	60	60	60	60

(\*\*= significant).

### Discussion Biochemical parametersGlycohemoglobin (HbA1c):

The results explain an important elevated in levels of HbA1c in DM2 compared with the control group, that is might be most exactly reflects the preceding 2-3 months of glycemic control, thus the patient with 2-3 months' period of DM., and bad organize to the disease so this situation lead to ahighy level of HbA1c in blood (Harris, 1998). The high level of HbA1C in this study was coordinated with other study by Kamran (2010) who reported the bad control to the long period as 2-3 months to the DM disease lead to higher HbA1c levels and diabetic difficulty (Kamran, 2010). This study showed a negative association among irisin with hemoglobin A1C (HbA1c). Thus, level of irisin might reveal the metabolic condition of patients suffer as of metabolic disorders. In adding to glycemic or HbA1c, "irisinemia" can also grow to be a new gifted idea to observe disorders of metabolism like obesity or T 2DM in future might be appear for a useful means in organization of metabolic diseases (Sanchis *et al.*, 2012).

A negative association has been shown in this study to the irisin values with insulin and HOMA-IR, this might be of all individuals in this study were health with BMI., (At the time indicated by the results of BMI in this study, which observing that it is within the standard range due to the World Health Organization. Association among irisin with insulin resistances confirming by the hypothesised participation of the "p-38-PGC1a- betatrophin pathway of irisin" (Sanchis-Gomar and Perez-Quilis 2014).

### Blood glucose:

The results showed a significant raise of blood sugar in DM2 compared with the control group. The confusion of beta cells in pancreas organ lead to reduce production of insulin hormone, if beta cells don't

make sufficient insulin, glucose accumulation in the blood in its place when absorbing by cells of the body, pre-diabetes or diabetes might be take place in this condition. The cells of body are hungry of energy in spite of high blood glucose levels in diabetes condition (Forouhi and Wareham, 2014).

#### **Irisin:**

Decreased of irisin level were observed in the DM2 compared with the control group, this might be because of the information that irisin was progressively reduced with decrease tolerance of glucose in quantity to insulin resistance or due to a high of fat at the expenditure of muscle mass for require of activity in patients with type2 DM, this explanation matched with the study which done by (Yan *et al.*, 2014; Assyov *et al.*, 2016).

So the irisin and myonectin, ruling by insulin resistance. Irisin and myonectin, are possible involved, in lipid and glucose metabolism, and thus possibly will be stop the development, of insulin resistance. on the other hand, their secretion could also be influence by the enlargement of muscle insulin resistance. Since irisin and myonectin showing to act in the adipose tissue, their deregulation might has an effect on the crosstalk between the tissues and further has a say to insulin resistance and impair glucose and lipid metabolism. Numerous studies found lesser circulating irisin levels in type 2 diabetic patients (Moreno-Navarrete *et al.*, 2013; Zhang *et al.*, 2014; Zhang *et al.*, 2016).

#### **Lipid profile:**

The results showed a significant increase in (triglyceride and Low density lipoprotein) of new onset patients. Typically, the dyslipidemia is reflected largely in enlarged serum levels of triglycerides and low levels of HDL, cholesterol levels may be very high in proteinuric patients (Schofield *et al.*, 2016). This results are corresponding with the result of Vaziri, (2003).

The model of dyslipidemia, in diabetes is different, from that in non diabetic people. This explain the significance of lipid and lipoprotein examination in diabetic patients and recommend a different lipid lowering agents from that used in non-diabetic population (Rustemeijer *et al.*, 1997). Accordingly, this study showed a negative association between irisin and cholesterol, might be that irisin possibly will inhibit the production of hepatic cholesterol through "AMPK-dependent inhibition of sterol regulatory element-binding proteins (SREBP2) and downstream of its genes target. Obstruction of irisin-induced adenosine monophosphate-activated protein kinase (AMPK) activation by complex C., or knockdown of "AMPK $\alpha$ 1" (Xiong *et al.*, 2015).

---

#### **C-Peptide:**

The necessary role of C-peptide is a helpful and broadly use method of assess pancreatic beta cell purpose (Jones and Hattersley, 2013; Leighton *et al.*, 2017), not as good as C-peptide levels have been linked with lesser glycemic organize and for this reason elevated HbA1c values (Lachin *et al.*, 2014; Kuhlreiber *et al.*, 2015) Decreases value of C-peptide and decrease beta cell function has been related to bigger levels of glucose change capability (Kramer *et al.*, 2014; Hope *et al.*, 2016).

---

#### **Insulin:**

In study by Fukushima *et al.*, 2016 in obese patients create the positive correlation between irisin and insulin resistance (Fukushima *et al.*, 2016), Though others reported either no association (Liu *et al.*, 2013; Choi *et al.*, 2013) or even a negative relationship (Yan *et al.*, 2014) among serum irisin with homeostatic model assessment of insulin resistance (HOMA-IR) score. Level of irisin was negative associated with BMI and insulin in our study individuals, this could be showed by the fact that all participants in our study were metabolically in good physical shape with BMI (At the time indicated by the results of BMI in our study, which showed that it is within the normal range according to the World Health Organization), table 2.

### Inflammatory Parameters:

#### Interleukin -6 (IL-6) and C-Reactive Protein (CRP):

Table I explained a significant increase ( $p \leq 0.05$ ) of IL-6 and CRP level in DM2 patients contrast with managed group. In this study the relationship research clarifies a positive association among irisin with both IL-6 and CRP in type 2 DM group.

A situation with chronic inflammatory might occur at the cellular level, with enlarge of the value of cytokines like IL-8, IL-15, and IL-6 from a pathway (in this study an indicator of chronic inflammatory was CRP, which tested elevated in the patient group (Pedersen *et al.*, 2003; Febbraio, 2007), reply, both the immunogenicity and number of auto-antibodies that contribute in role in autoimmune incident, could raise. PGC-1 $\alpha$ , through another pathway, raises of "FNDC5" level and leads to elevate of irisin concentration (Aydin, 2014). Therefore, both irisin and auto-antibody values might be highly by the "PGC-1 $\alpha$ " activation. So far, our clarification supports our results up to the correlation analysis branch.

---

### Conclusion:

- 1- The level of irisin in the type 2 patients reduced with highly level of HOMO-IR and BMI.
  - 2- From the results of correlation analysis between irisin and inflammatory factors we can concluded that irisin work as a anti agents of the inflammatory condition.
  - 3-The negative correlation between irisin and glucose refer to the important of it on the glucose homeostasis.
- 

### References:

1. Allian, C.C.; Poon, L.S.; Chan, C.S.; Richmond, W. and FU, P.C. (1974) "Enzymatic Determination of Total Serum Cholesterol." *Clinical Chem.* 20, (4): 470–75.
2. Arias-Loste, M. T., Ranchal, I., Romero-Gómez, M., and Crespo, J. (2014). Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. *International journal of molecular sciences*, 15(12), 23163-23178.
3. Assyov Y., Gateva A., Tsakova A., Kamenov Z. (2016). Irisin in glucose continuum. *Exp. Clin. Endocrinol. Diabetes*; 124: 22–27.
4. Aydin, S. (2014). Three new players in energy regulation: preptin, adropin and irisin. *Peptides*, 56, 94-110.
5. Azadbakht, L., Kimiagar, M., Mehrabi, Y., Esmailzadeh, A., Hu, F. B., & Willett, W. C. (2007). Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. *Diabetes care*, 30(4), 967-973.
6. Badimon, J. J., Badimon, L., & Fuster, V. (1990). Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. *The Journal of clinical investigation*, 85(4), 1234-1241.
7. Bains, S., Anyaeche, C., Wyatt, A., Coker, O., & Bolodeoku, J. (2017). Evaluation of Point of Care Test (POCT), i-CHROMA™ Serum C-Reactive Protein (CRP) Assay and Microalbumin Urine (MAU) Methods. *Annals of Clinical and Laboratory Research*, 5(3), 192.
8. Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., and Kajimura, S. (2012). A PGC1- $\alpha$ -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature*, 481(7382), 463-8.
9. Choi, Y. K., Kim, M. K., Bae, K. H., Seo, H. A., Jeong, J. Y., Lee, W. K., and Park, K. G. (2013). Serum irisin levels in new-onset type 2 diabetes. *Diabetes research and clinical practice*, 100(1), 96-101.

10. Ebert, T., Focke, D., Petroff, D., Wurst, U., Richter, J., Bachmann, A., and Bast, I. (2014). Serum levels of the myokine irisin in relation to metabolic and renal function. *European journal of endocrinology*, 170(4), 501-506.
11. Endocrinologica, M. (2017). Irisin as a regulator of bone and glucose metabolism: a narrative review. *Minerva endocrinologica*.
12. Espes, D., Lau, J., and Carlsson, P. O. (2015). Increased levels of irisin in people with long-standing Type 1 diabetes. *Diabetic medicine*, 32(9), 1172-1176.
13. Febbraio, M. A. (2007). Exercise and inflammation.
14. Forouhi, N. G., & Wareham, N. J. (2014). Epidemiology of diabetes. *Medicine (Abingdon)*. 42 (12): 698–702.
15. Fukushima, Y., Kurose, S., Shinno, H., Cao Thi Thu, H., Tamanoi, A., Tsutsumi, H., and Kimura, Y. (2016). Relationships between serum irisin levels and metabolic parameters in Japanese patients with obesity. *Obesity science & practice*, 2(2), 203-209.
16. Harris, M. I. (1998). Diabetes in America: epidemiology and scope of the problem. *Diabetes care*, 21(Supplement 3), C11-C14.
17. Hope, S. V., Knight, B. A., Shields, B. M., Strain, W. D., Hattersley, A. T., Choudhary, P., and Jones, A. G. (2016). Low c-peptide is associated with high glycaemic variability and hypoglycaemia in insulin-treated patients with type 2 diabetes. *Diabet Med*, 33, 144.
18. Jeppsson, J. O., Kobold, U., Barr, J., Finke, A., Hoelzel, W., Hoshino, T., ... & Thienpont, L. (2002). Approved IFCC reference method for the measurement of HbA1c in human blood. *Clinical chemistry and laboratory medicine*, 40(1), 78-89.
19. Jones, A. G., and Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*, 30(7), 803-817.
20. Kamran M. A. (2010). Association between high risk foot, retinopathy and hba1c in saudi diabetic population. *Pak J Physiol.*, 622-28.
21. Kramer, C. K., Choi, H., Zinman, B., and Retnakaran, R. (2014). Glycemic variability in patients with early type 2 diabetes: the impact of improvement in  $\beta$ -cell function. *Diabetes Care*, DC\_132591.
22. Kuhlreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold III, P., Burger, D and Faustman, D. L. (2015). Low levels of C-peptide have clinical significance for established Type 1 diabetes. *Diabetic Medicine*, 32(10), 1346-1353.
23. Lachin, J. M., McGee, P., Palmer, J. P., and DCCT/EDIC research group. (2014). Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. *Diabetes*, 63(2), 739-748.
24. Leighton, E., Sainsbury, C. A., and Jones, G. C. (2017). A practical review of C-peptide testing in diabetes. *Diabetes therapy*, 8(3), 475-487.
25. Liu, J. J., Wong, M. D., Toy, W. C., Tan, C. S., Liu, S., Ng, X. W., .and Lim, S. C. (2013). Lower circulating irisin is associated with type 2 diabetes mellitus. *Journal of Diabetes and its Complications*, 27(4), 365-369.
26. Miyazawa, H., Bannai, H., Yanase, T., Morita, C., Satoh, S., Sugiyama, J., ... & Inouye, S. (1999). A reverse-sandwich enzyme-linked immunosorbent assay for verocytotoxin 1 and 2 antibodies in human and bovine sera. *Clin. Diagn. Lab. Immunol.*, 6(5), 701-704.
27. Moreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G., Tinahones, F., and Fernández-Real, J. M. (2013). Irisin is expressed and produced by human muscle and adipose



- tissue in association with obesity and insulin resistance. *The Journal of Clinical Endocrinology & Metabolism*, 98(4), E769-E778.
28. Nuttall, F. Q. (2015). Body mass index: obesity, BMI, and health: a critical review. *Nutrition today*, 50(3), 11.
29. Pedersen, B. K., Steensberg, A., Fischer, C., Keller, C., Keller, P., Plomgaard, P., and Saltin, B. (2003). Searching for the exercise factor: is IL-6 a candidate? *Journal of Muscle Research & Cell Motility*, 24(2-3), 113.
30. Peter O. and Kwiterovich, Jr., M.D. (2004). *Diagnostics, R., & Diagnostics, B. M. Laboratory Procedure Manual. Laboratory Procedure Manual*, 410-614-1030.
31. Rustemeijer, C.; Schouten, J. A.; Janssen, E. N.; Spooren, P. F. and Van Doormaal, J. J. (1997). Pravastatin in diabetes associated hypercholesterolemia. *Acta. diabetol.*, 34(4): 294-300.
32. Sanchis-Gomar, F., & Perez-Quilis, C. (2014). The p38–PGC-1 $\alpha$ –irisin–betatrophin axis: Exploring new pathways in insulin resistance. *Adipocyte*, 3(1), 67-68.
33. Sanchis-Gomar, F., Lippi, G., Mayero, S., Perez-Quilis, C., & García-Giménez, J. L. (2012). Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. *Journal of diabetes*, 4(3), 196-196.
34. Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016). Diabetes dyslipidemia. *Diabetes Therapy*, 7(2), 203-219.
35. Trinder, P. (1969). Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. *Annals of clinical Biochemistry*, 6(1), 24-27.
36. Vaziri, N. D.; Sato, T. and Liang, K. (2003). Molecular mechanism of expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. hypercholesterolemia. *Acta. diabetol.*, 34(4): 294-300.
37. World Health Organization. (2016). *World health statistics 2016: monitoring health for the SDGs sustainable development goals*. World Health. Organization.
38. Xiong, X. Q., Chen, D., Sun, H. J., Ding, L., Wang, J. J., Chen, Q., and Gao, X. Y. (2015). FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, 1852(9), 1867-1875.
39. Yan, B.; Shi, X.; Zhang, H.; Pan, L. and Ma, Z. et al. (2014). Association of Serum Irisin with Metabolic Syndrome in Obese Chinese Adults. *PLoS ONE.*, 9(4).
40. Zhang, C., Ding, Z., Lv, G., Li, J., Zhou, P., & Zhang, J. (2016). Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta analysis meta. *Journal of diabetes*, 8(1), 56-62.
41. Zhang, M., Chen, P., Chen, S., Sun, Q., Zeng, Q. C., Chen, J. Y., and Wang, J. K. (2014). The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. *Eur Rev Med Pharmacol Sci*, 18(11), 1567-72.